Phase II Single Arm Study of Gemcitabine and Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer
Phase of Trial: Phase II
Latest Information Update: 16 Apr 2018
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Pembrolizumab (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 10 Mar 2017 Planned End Date changed from 1 Apr 2020 to 1 May 2024.
- 10 Mar 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Sep 2019.
- 01 Jul 2016 Status changed from not yet recruiting to recruiting.